Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats

AIM: To investigate the protective effects of ethyl pyruvate (EP) on acute-on-chronic liver failure (ACLF) in rats. METHODS: An ACLF model was established in rats, and animals were randomly divided into normal, model and EP treatment groups. The rats in EP treatment group received EP (40 mg/kg) at 3 h, 6 h, 12 h and 24 h after induction of ACLF. Serum endotoxin, high mobility group box-1 (HMGB1), alanine transaminase (ALT), tumor necrosis factor-alpha (TNF-alpha), interferon-alpha (IFN-gamma), interleukin (IL)-10 and IL-18 levels, changes of liver histology and HMGB1 expressions in liver tissues were detected at 48 h after induction of ACLF. The effects of EP on the survival of ACLF rats were also observed. RESULTS: Serum levels of endotoxin (0.394 +/- 0.066 EU/mL vs 0.086 +/- 0.017 EU/mL, P < 0.001), HMGB1 (35.42 +/- 10.86 mu g/L vs 2.14 +/- 0.27 mu g/L, P < 0.001), ALT (8415.87 +/- 3567.54 IU/L vs 38.64 +/- 8.82 IU/L, P < 0.001), TNF-alpha (190.77 +/- 12.34 ng/L vs 124.40 +/- 4.12 ng/L, P < 0.001), IFN-gamma (715.38 +/- 86.03 ng/L vs 398.66 +/- 32.91 ng/L, P < 0.001), IL-10 (6.85 +/- 0.64 ng/L vs 3.49 +/- 0.24 ng/L, P < 0.001) and IL-18 (85.19 +/- 3.49 ng/L vs 55.38 +/- 1.25 ng/L, P < 0.001) were significantly increased, and liver tissues presented severe pathological injury in the model group compared with the normal group. However, EP administration significantly improved hepatic histopathology and reduced the serum levels of endotoxin (0.155 +/- 0.045 EU/mL vs 0.394 +/- 0.066 EU/mL, P < 0.001) and inflammatory cytokines (11.13 +/- 2.58 mu g/L vs 35.42 +/- 10.86 mu g/L for HMGB1, 3512.86 +/- 972.67 IU/L vs 8415.87 +/- 3567.54 IU/L for ALT, 128.55 +/- 5.76 ng/L vs 190.77 +/- 12.34 ng/L for TNF-alpha, 438.16 +/- 38.10 ng/L vs 715.38 +/- 86.03 ng/L for IFN-gamma, 3.55 +/- 0.36 ng/L vs 6.85 +/- 0.64 ng/L for IL-10, and 60.35 +/- 1.63 ng/L vs 85.19 +/- 3.49 ng/L for IL-18, respectively, P < 0.001), and the levels of HMGB1 in liver tissues regardless of treatment time after induction of ACLF. EP treatment at the four time points prolonged the median survival time of ACLF rats (60 h) to 162 h, 120 h, 102 h and 78 h, respectively (chi(2) = 41.17, P < 0.0001). CONCLUSION: EP administration can protect against ACLF in rats, and is a potential and novel therapeutic agent for severe liver injury. (C) 2012 Baishideng. All rights reserved.